Articles related to DRUG SAFETY & INTERACTIONS

Adverse events from compounded semaglutide have led to hundreds of hospitalizations, highlighting critical safety concerns for healthcare providers managing patients seeking weight loss solutions.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

Risk of dementia with these medications increases proportionally with higher doses and extended duration of use, emphasizing the importance of minimal effective dosing strategies.

High-potency cannabis use has emerged as a significant factor in cyclic vomiting presentations, requiring clinicians to carefully evaluate usage patterns and consider CHS in their differential diagnosis.

In patients with heart failure and preserved ejection fraction, finerenone demonstrated a 16% reduction in the primary composite endpoint of total worsening heart failure events and cardiovascular death compared to placebo.